SCN9A and peripheral neuropathy: The cohort study on oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients with gastric, pancreatic, and biliary cancers revealed that individuals with SCN9A rs6746030 (NaV1.7) and SCN10A rs12632942 (NaV1.8) polymorphic variants developed chronic OXAIPN or experienced greater severity of chronic OXAIPN (Palugulla et al., 2017).